Evidence map›Paper›PMID 41899521›Full record

ArticleCancers2026

Association Between Patient-Reported Outcomes and Overall Survival in Patients with Advanced NSCLC Treated with First-Line Cemiplimab-Based Therapy.

David R Gandara, Tamta Makharadze, Mahmut Gümüş, Miranda Gogishvili, Ahmet Sezer, Eric Kim, Eric Yan, Frank Seebach, James Harnett, Ruben G W Quek

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

David R GandaraDivision of Hematology/Oncology, Department of Medicine, UC Davis Comprehensive Cancer Center, 2279 45th Street, Sacramento, CA 95817, USA.
Tamta MakharadzeLTD High Technology Hospital Medical Center, 118 Pushkini Street, 6000 Batumi, Georgia.ORCID 0000-0001-6432-1872
Mahmut GümüşDepartment of Medical Oncology, School of Medicine, Istanbul Medeniyet University, Dumlupınar D100 Karayolu No. 98, 34720 Kadiköy, Istanbul, Turkey.
Miranda GogishviliHigh Technology Medical Centre, University Clinic Ltd., 9 Tsinandali Street, 0144 Tbilisi, Georgia.
Ahmet SezerDepartment of Medical Oncology, Başkent University, Kazım Karabekir, Gülhatmi Cd. 37/A, 01120 Adana, Adana Province, Turkey.ORCID 0000-0002-6445-1439
Eric KimRegeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA.
Eric YanCyan Global Inc., 5965 Village Way STE 105-118, San Diego, CA 92130, USA.
Frank SeebachRegeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA.
James HarnettRegeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA.
Ruben G W QuekRegeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA.ORCID 0000-0001-9602-3239

Funding

Regeneron Pharmaceuticals, Inc. n/a
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cemiplimabimmunotherapynon-small-cell lung cancerpatient-reported outcomes

Identifiers

PMID41899521
PMCPMC13024962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.